tirzepatide dysesthesia 28.7% Weight Loss in New Retatrutide Study – Dr Brad Stanfield Retatrutide Dysesthesia: What's Happening Under

[1] [5] Currently available GLP-1 medications in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist

Lindsey sees patients at our Spring Branch clinic on US-281

doi:10.4049/jimmunol.1500418

In the global TRIUMPH-4 trial, adults with obesity and knee osteoarthritis treated with the highest dose of retatrutide lost an average of 28.7% of their body weight over 68 weeks roughly 32 kg per patient while also showing marked improvements in pain and physical function related to osteoarthritis